Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fentanyl Patches Need Additional Safety Precautions, ISMP Recommends

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J has submitted a risk management plan to FDA for its fentanyl patch Duragesic.

You may also be interested in...

Duragesic Public Health Advisory Follows Palladone Withdrawal

FDA is investigating reports of deaths associated with overdoses of the fentanyl patch (J&J’s Duragesic and generics). As with Purdue’s opioid Palladone, alcohol consumption is cited as a possible factor in increased fentanyl release or effect.

J&J Duragesic “Black Box” Adds Fentanyl Abuse Warning

Revised labeling also narrows the indicated population and warns about drug-drug interactions with CYP 3A4 inhibitors. FDA notes J&J is in “discussions with the agency regarding establishment of a risk management program.” Labeling changes were approved one week after Duragesic generics entered the market.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts